Well Referenced

Tag: benfotiamine

A Review of Alternative Treatment Options in Diabetic Polyneuropathy

This 2021 narrative review evaluates non-conventional treatment modalities for diabetic polyneuropathy (DPN), a common yet difficult-to-treat diabetes complication. It discusses pharmacologic and non-pharmacologic alternatives such as topical agents (capsaicin, lidocaine), nutritional supplements (alpha-lipoic acid, benfotiamine, acetyl-L-carnitine), and non-invasive modalities (acupuncture, electrical nerve stimulation). While several of these interventions demonstrated symptom

Read More »
June 26, 2025 No Comments

Impaired Nicotinamide Adenine Dinucleotide (NAD⁺) Metabolism in Diabetes and Diabetic Tissues: Implications for Nicotinamide-Related Compound Treatment

This 2020 review explores how diabetes disrupts NAD⁺ metabolism, leading to reduced NAD⁺/NADH ratios (pseudohypoxia) due to increased substrate oxidation. In type 1 diabetes, NAD⁺ depletion is driven by poly(ADP-ribose) polymerase (PARP) activation, while in type 2 diabetes, decreased AMP-activated protein kinase (AMPK) activity impairs NAD⁺ biosynthesis via downregulation of

Read More »
June 26, 2025 No Comments

Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose

This study investigated the effects of thiamine and benfotiamine on glucose metabolism in vascular cells cultured in high glucose conditions. Both thiamine and benfotiamine significantly reduced aldose reductase activity, sorbitol accumulation, and intracellular glucose levels while increasing transketolase activity, thereby promoting the pentose phosphate pathway. These findings suggest that thiamine

Read More »
June 26, 2025 No Comments

Therapeutic potential of benfotiamine and its molecular targets

This review article explores the therapeutic potential of benfotiamine, a lipid-soluble derivative of thiamine (vitamin B1), highlighting its superior bioavailability and its ability to activate transketolase—an enzyme that diverts harmful glycolytic intermediates from pathways that lead to advanced glycation end products (AGEs), a key factor in diabetic vascular complications. Benfotiamine

Read More »
June 26, 2025 No Comments

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

The study “Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy,” published in Nature Medicine (2003), investigated benfotiamine, a lipid-soluble form of thiamine (vitamin B1), and its ability to prevent diabetic retinopathy by simultaneously inhibiting three harmful metabolic pathways activated by high blood sugar—the hexosamine, DAG-PKC,

Read More »
June 26, 2025 No Comments